Summary The matrix metalloproteinases (MMPs) are perceived as essential for tumour invasion and metastases. The purpose of this study was to determine the expression and cellular localisation of the 92 kDa type IV collagenase (MMP-9) protein and mRNA in human colorectal cancer (CRC). In CRC and matched normal mucosa specimens from 26 CRC patients, Northern blot hybridisation and Western blot analyses provide convincing evidence that MMP-9 is expressed in greater quantities in CRC than in normal tissue. The MMP-9 tumour to normal mucosa fold-increase (T/N) was 9.7+7.1 (mean+s.d.) (P<0.001) for RNA and 7.1 + 3.9 (P< 0.001) for protein. The sites of MMP-9 mRNA and protein synthesis were colocalised in tumour stroma by in situ hybridisation and immunohistochemistry in 26 CRC samples. Both MMP-9 mRNA and protein signals were strongest in the population of stromal cells concentrated at the tumour-stroma interface of an invading tumour. Furthermore, MMP-9-positive cells were identified as macrophages using an antimacrophage antibody (KP1) in serial sections from ten CRC samples. Given the persistent localisation of MMP-9-producing macrophages to the interphase between CRC and surrounding stroma, our observations suggest that MMP-9 production is controlled, in part, by tumour-stroma cell interactions. Further studies are needed to determine the in vivo regulation of MMP-9 production from infiltrating peritumour macrophages.
(MMP-1, MMP-8 and MMP-13), type IV collagenases/ gelatinase (MMP-2 and MMP-9), stromelysins (MMP-3 and MMP-10), membrane-type MMPs [MT-MMP1 (Sato et al., 1994) , MT-MMP2 (Will and Hinzmann, 1995) , MT-MMP3 (Takino et al., 1995) and MT-MMP4 (Puente et al., 1996) ]. However, several MMPs including, stromelysin 3 (MMP-11) (Noel et al., 1995) and macrophage metalloelastase (Woessner, 1994; Birkedal-Hansen, 1995) do not appear to belong to any one group.
An important role for MMPs in invasion and metastases is supported by studies demonstrating a correlation between elevated MMP levels and the metastatic phenotype in cell cultures (Ballin et al., 1988; Moll et al., 1990; TurpeenniemiHujanen et al., 1985; Yamagata et al., 1988) , animal models (Nakajima et al., 1990) and several human tumours (Muller et al., 1991; McDonnell et al., 1991; Hamdy et al., 1994; Levy et al., 1991; Stearns and Wang, 1993; Rao et al., 1993; Yoshimoto et al., 1993; Kossakowska et al., 1993; Brown et al., 1993; Naylor et al., 1994) .
Since type IV collagen is a major component of BM, the 72 kDa (MMP-2) and 92 kDa (MMP-9) type IV collagenase are of particular interest. In order to understand further in vivo type IV collagenase regulation, knowledge of the in vivo sources of MMP-2 and MMP-9 production is essential. However, owing to conflicting reports localising MMP-2 mRNA to peritumour stromal fibroblasts (Poulsom et al., 1992; Pyke et al., 1993) and MMP-2 protein to CRC cells themselves (Levy et al., 1991) , the cellular origin of MMP-2 within CRC specimens remains unclear. Similarly, although microdissection studies on human CRC specimens localise increased pro-MMP-9 enzyme to the invasive CRC edge (Emmert-Buck et al., 1994) , the cellular source of MMP-9 remains uncertain, since MMP-9 mRNA signals have been localised to the peritumour stromal compartment of breast Davies et al., 1993a) , skin (Pyke et al., 1992) , bladder (Davies et al., 1993b) and colorectal cancers Newell et al., 1994; , while MMP-9 immunostaining has been localised within CRC cells as well as peritumour stromal neutrophils and macrophages (Jeziorska et al., 1994) .
Furthermore, in human osteoclastomas, both MMP-9 RNA and protein have been localised to multinucleated giant cells (Wucherpfennig et al., 1994) . In order to clarify the discrepancy in the cellular origin of CRC MMP-9, we examined the simultaneous mRNA and protein pattern of MMP-9 expression in human CRC specimens. In situ hybridisation Our techique for MMP-9 in situ hybridisation has been previously described in detail . Briefly, the sense and antisense transcripts were prepared from a human MMP-9 cDNA insert (1059 bp extending from nucleotides 7 to 1066) subcloned in Bluescript KS (Stratagene). The MMP-9 sense probe was generated by T3 polymerase following digestion with XbaI, while the antisense probe was generated by T7 Tissue sections were counterstained with haematoxylin and eosin (H&E). The sections were examined by dark-field microscopy.
Materials and methods

Monoclonal antibody
The monoclonal antibody (MAb) MMP-9 (Ab-2) (clone 7-1 IC) was obtained from Oncogene Science, Inc. (Manhassett, NY, USA). This MAb is generated by immunising mice with MMP-9 protein partially purified from the conditioned media of PMA-stimulated HT1080 human fibrosarcoma cells (Ramos-DeSimone et al., 1993) . MMP-9 (Ab-2) recognises the latent (92 kDa) form of human MMP-9. The active (82 kDa) form of human MMP-9 cannot be recognised by this antibody (Ramos-DeSimone et al., 1993) . MAb MMP-9 (Ab-2) was used for both Western blot and immunohistochemistry. The anti-human macrophage monoclonal antibody, CD-68 (KP-1), was obtained from Dako Corporation (Glostrup, Denmark). This antibody is known to react with macrophages in a wide variety of human tissues, including Kupffer's cells and macrophages in the red pulp of the spleen, in the lamina propria of the gut, in lung alveoli and in bone marrow (Pulford et al., 1989) . However, not all haematopoietic cells react with KP1 antibody (Thalmeier et al., 1994) .
Western blot analysis The tissue was homogenised in Tris buffer (50 mM Tris-HCl, pH 7.5, containing 75 mM sodium chloride) and centrifuged at 5000 x g for 20 min as previously described (Zeng et al., 1994a) . The supernatant of tumour and paired normal mucosa (25 ,ug) were electrophoresed on a 8% sodium dodecyl sulphate-polyacrylamide gel electrophoresis gel using a MINIGEL apparatus (Bio-Rad, Richmond, CA, USA). Separated proteins were transferred to nitrocellulose membranes (Amersham, Bucks, UK) in Tris/glycine buffer (2.5 mM Tris, 192 mM glycine and 20% methanol) at 4°C and 100 V using a MINI system. Non-specific binding sites were blocked for 1 h at room temperature in 10 mM Tris buffer containing 150 mm sodium chloride and 0.5% Tween 20 (TBS-T) with 4% bovine serum albumin (BSA) . The blots were incubated overnight at 4°C in a 1:500 dilution of MMP-9 MAb Ab-2. The blot was washed several times with TBS-T, followed by an incubation step with horseradish peroxidaselabelled anti-rabbit antibody (1:5000 in TBS-T for 30 min at room temperature). After washing with TBS-T, an enhanced chemiluminescence detection system (ECL, Amersham) was used. For molecular weight determination, ECL protein molecular weight and rainbow coloured protein molecular weight markers (Amersham) were used.
Immunohistochemistry
For immunohistochemical staining, the slides were processed by use of the Vectastain ABC Elite kits (Vector Laboratories, Inc., Burlingame, CA, USA) according to the manufacturer's protocol as previously described (Zeng et al., 1994b Densitometric quantitation MMP-9 RNA and protein levels were quantitated by measuring the intensities of the appropriate autoradiographic bands using LKB XL laser densitometry (Pharmacia LKB Biotechnology, Uppsala, Sweden).
The RNA results were expressed as the fold-increase of a 2.8 kilobase MMP-9 transcript in tumours to that in the paired normal tissues. The 28S transcript was used as an internal control: T/N (Tumour/Normal mucosa)= TMMpg:T28s/NMMpg:N28S
The MMP-9 protein levels are expressed as the foldincrease in expression of the 92 kDa bands in tumour relative to that measured in the corresponding adjacent normal mucosa.
Differences of both RNA and protein levels between tumour and paired normal tissue were analysed by Student's t-test.
Results
Determination of tumour-normal MMP-9 RNA level Total cellular RNA of human CRC and paired adjacent normal mucosa from 26 CRC patients was examined for expression of MMP-9 RNA by Northern blot hybridisation. Figure 1 is a representative Northern blot hybridisation of five CRC patients. The 2.8 kb MMP-9 transcript was strongly expressed in tumour compared with the extremely low levels noted in normal mucosa. Densitometric analyses of blots indicated that MMP-9 was overexpressed in all primary CRCs when compared with corresponding normal mucosa. The T/N fold-increase of MMP-9 RNA ranged from 1.3 to 25.7 with a mean+standard deviation (s.d.) of 9.7+7.1. MMP-9 RNA expression was significantly increased in primary CRC relative to adjacent normal mucosa (P<0.001).
Determination of tumour-normal MMP-9 protein level The expression of MMP-9 protein in the CRC was detected by Western blot analysis. A 92 kDa band representative of MMP-9 protein was increased in the tumour compared with normal mucosa (Figure 2 ). Based upon MMP-9 protein densitometric quantitation, the mean MMP-9 protein tumour to normal mucosa fold-increase was 7.1 + 3.9 (mean + s.d.) (P< 0.001).
Cellular localisation of MMP-9 mRNA by in situ hybridisation The cellular localisation of MMP-9 RNA within CRC tissues was examined by in situ hybridisation using an antisense MMP-9 RNA probe. Eighteen out of 26 (69.2%) CRCs had detectable signals for MMP-9 mRNA. The predominance of MMP-9-positive cells was limited to the interface between tumour and surrounding normal mucosa and shows a punctate pattern of localisation (Figure 3a and b) . MMP-9-positive signals were located in stromal cells encircling the tumour epithelial cells but not in tumour cells themselves (Figure 3c (Figure 4c and d higher magnification, bordered by arrows in Figure 4c ) demonstrates MMP-9 antigen concentration at the invading front between tumour and normal mucosa. Figure 4e and f (higher magnification, bordered by arrows in Figure 4e ) further emphasises that MMP-9 protein-positive cells are located principally in the peritumour stroma. Higher magnification (Figure 4d and f) reveals that MMP-9-positive cells have a macrophage-like morphology.
To identify the cells expressing MMP-9 protein, serial sections from ten CRC samples were examined immunohistochemically with both MMP-9 and macrophage-specific antibodies (CD-68) (Pulford et al., 1989) . Figure 5a and c reveals anti-MMP-9 MAb and anti-macrophage MAb staining respectively. As noted, MMP-9-positive cells and macrophages have a similar distribution. At higher magnification (Figure 5b and d) , MMP-9-positive cells with a macrophage-like morphology correspond directly with the cells staining positive for macrophages. 
Discussion
Based upon both Northern and Western blot data, as well as in situ hybridisation and immunohistochemical staining, our results provide convincing evidence that MMP-9 is significantly overexpressed in CRC and that the sites of production are the peritumour stromal cells rather than the cancer cells themselves. These results, along with our previous zymographic studies demonstrating increased levels of active MMP-9 (82 kDa) in CRC specimens from patients with metastases , suggest an important role for MMP-9 production in CRC invasion and metastases.
In addition to studies demonstrating a correlation between MMP-9 expression and invasion and metastases (Ballin et al., 1988; Moll et al., 1990; Turpeenniemi-Hujanen et al., 1985; Yamagata et al., 1988 ), a recent transfection study directly links MMP-9 expression to the metastatic phenotype (Bernhard et al., 1994) . Although in vitro, TGF-a, EGF and TGF-,B up-regulate MMP-9 expression (Birkedal-Hansen et al., 1993) , and natural tissue inhibitor proteins, such as tissue inhibitor of metalloproteinase (TIMP) Matrisian, 1992) inhibit MMP activity, the in vivo regulation of MMP-9 remains unknown. This is, in part, owing to the uncertainty of the cellular origin of MMP-9 and its site of activation.
In vitro, a variety of cell types including fibroblasts, endothelial cells, keratinocytes, macrophages and eosinophils produce (Werb and Alexander, 1993; Saarialho-Kere et al., 1993) . In human squamous cell carcinomas, Pyke et al. (1992) have demonstrated that MMP-9 mRNA is expressed by stromal macrophages, whereas Stahle-Backdahl and Parks (1993) noted that tissue eosinophils produce MMP-9. In human CRC, data from Pyke et al. (1993) and our own demonstrate that MMP-9 mRNA may be produced by peritumour macrophages. In the present study, we demonstrate that MMP-9 protein, detected with an MMP-9 monoclonal antibody, also localises to the peritumour macrophages. The lack of a complete concordance between the immunohistochemical staining pattern of MMP-9-positive cells and macrophages suggests that either serial adjacent sections are not 100% morphologically identical or other stromal cells, such as neutrophils (Jeziorska et al., 1994; Nielsen et al., 1996) , eosinophils (Stahle-Backdahl and Parks, 1993) , fibroblasts or endothelial cells may also be producing Although the in vivo regulation of MMPs remains undefined, the localisation of several MMPs to tumour stromal cells rather than tumour cells themselves (Pyke et al., 1992; 1993; Cottam and Rees, 1993; Davies et al. 1993a ,b Canete-Soler et al., 1994 suggests that stromal cells may be involved in this process. Basset et al. (1990) and Wolf et al. (1993) first demonstrated both mRNA and protein expression of MMP-1 1 (stromelysin) in the tumour stroma of human breast carcinoma. However, current evidence suggests that the mRNA and protein expression of other MMPs may be in either tumour or stromal cells. In CRC, matrilysin (MMP-2) mRNA is produced by benign and malignant cells (Cottam and Rees, 1993) . In contrast, mRNA of other MMPs, such as MMP-2, 3, 7, 9, 11 appear to be restricted to tumour stromal cells Cottam and Rees, 1993; . Although MMP-2 mRNA has been found exclusively in fibroblasts, MMP-2 protein has been localised to the surface of cancer cells (Pyke et al., 1992 . Discrepancies between MMP-2 mRNA and protein cellular expression suggest distinct sites of MMP-2 RNA production ocakabon of NW-9 mRNA and protek in coloncancer stroma C a ZS Zeng and JG Guillem 1166 and MMP-2 protein utilisation (Levy et al.. 1991; Mackay et al.. 1992 Although evidence supports a complex membraneassociated regulation of MMP-2, involving TIMPs, the recently described membrane activators (MT-MMP) and a cell surface MMP-2 binding protein (Birkedal-Hansen. 1995; Young et al., 1995; Yu et al., 1995) , less is known about MMP-9 activation. In *itro. stromelysin-I (MMP-3), TIMP-2, plasmin. kallikrein (Birkedal-Hansen, 1995) , and most recently, MMP-2 (Fridman et al., 1995) , have been shown to activate MMP-9. However, the localisation of MMP-9 mRNA to the stroma of breast (Davies et al., 1993a) , bladder (Davies et al.. 1993b ) and skin cancer (Pyke et al., 1992) and CRC suggests a stromal source of MMP-9 in several human cancers. Our present results demonstrating colocalisation of both MMP-9 mRNA and protein to pentumour macrophages suggest that peritumour macrophages are both a source of MMP-9 production and a site of localisation and, therefore, a possible site of utilisation.
The localisation of MMP-9 around tumour blood vessels (Davies et al.. 1993b ) also suggests that MMPs may facilitate angiogenesis via enhanced ECM turnover. Furthermore, the localisation of MMP-9 signals to the interface between cancer and stromal cells suggests probable cancer-stromal cell interactions in the regulation of macrophage MMP-9 production. Although certain factors produced from cancer cells. such as tumour collagenase-stimulating factor (TCSF).
can stimulate fibroblast MMP-2 production (Kataoka et al.. 1993), it does not appear to stimulate MMP-9 production. However, the observation that mitogens, such as lipopolvsaccharide (LPS), can stimulate the production of both MMP-2 and MMP-9 from murine peritoneal macrophages (Sledge et al., 1995) , as well as our recent coculture experiments demonstrating induction of monocyte-MMP release by metastatic CRC cells (Swallow et al., 1996) . support the notion that in vivo CRC cells may activate macrophage MMP production in a paracrine-like manner. Alternative explanations include CRC cell-mediated chemoattraction of activated macrophages, which express MMP-9. or induction of MMP-9 gene expression in resident macrophages (Mantovani and Semeraro. 1995) .
In summary, we have demonstrated that MMP-9 RNA and protein expression are significantly elevated in CRC when compared with corresponding normal mucosa. The distribution of MMP-9 mRNA and protein in CRC tissues is similar and appears to localise to macrophages at the interface between cancer cells and surrounding normal tissue. Further studies are needed to determine the in vivo regulation of production from infiltrating peritumour macrophages as well as to delineate cancer -stromal cellular interactions.
